HC Wainwright Has Bearish Outlook for PLX FY2025 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Research analysts at HC Wainwright decreased their FY2025 earnings per share estimates for shares of Protalix BioTherapeutics in a report issued on Friday, November 21st. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.03 for the year, down from their previous forecast of $0.05. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2025 earnings at $0.04 EPS, Q1 2026 earnings at $0.04 EPS, Q2 2026 earnings at $0.05 EPS, Q3 2026 earnings at $0.05 EPS and Q4 2026 earnings at $0.06 EPS.

Protalix BioTherapeutics Stock Performance

PLX opened at $1.75 on Monday. Protalix BioTherapeutics has a fifty-two week low of $1.32 and a fifty-two week high of $3.10. The firm has a 50-day moving average of $2.18 and a 200 day moving average of $1.78. The firm has a market cap of $140.74 million, a P/E ratio of -13.46 and a beta of -0.18.

Institutional Investors Weigh In On Protalix BioTherapeutics

A number of hedge funds have recently modified their holdings of PLX. Geode Capital Management LLC purchased a new position in Protalix BioTherapeutics in the second quarter valued at approximately $1,223,000. Stratos Wealth Partners LTD. lifted its position in shares of Protalix BioTherapeutics by 42.9% during the 3rd quarter. Stratos Wealth Partners LTD. now owns 500,000 shares of the company’s stock valued at $1,110,000 after buying an additional 150,000 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Protalix BioTherapeutics by 2.8% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 496,216 shares of the company’s stock valued at $734,000 after buying an additional 13,341 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Protalix BioTherapeutics by 159.0% during the 1st quarter. Jane Street Group LLC now owns 294,318 shares of the company’s stock worth $753,000 after acquiring an additional 180,702 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in Protalix BioTherapeutics by 482.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 289,461 shares of the company’s stock worth $741,000 after acquiring an additional 239,751 shares during the last quarter. Institutional investors own 16.53% of the company’s stock.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.